This cross-sectional study found that fasting glucagon levels are independently associated with the risk of CAD in female patients with T2DM.These results suggest that glucagon may play an important role in the cardiovascular pathology of female T2DM patients and could be a potential novel biomarker for CAD risk. Here, GCG is linked to type 2 diabetes mellitus.